Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 4c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.43 --0%
EPS Growth %: -60.5%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
CAN, UNFI, SUNB, More
EPS Growth %: -60.5%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
CAN, UNFI, SUNB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of $0.00, $0.04 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $38.82 million versus the consensus estimate of $44.5 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Roth/MKM Downgrades eGain Corporation (EGAN) to Neutral
- UBS Upgrades Eaton Corporation (ETN) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
